
The new zzso and the new zzso forms, now available in France, require an update in zzso zzso The purpose of the present study is to help those prescribing select the appropriate zzso and its zzso form for pain zzso 

zzso of pharmacological properties of zzso zzso zzso and zzso zzso of zzso modes of prescription and use of main zzso for pain (especially cancer zzso Examples for calculating required drug dosage depending on the clinical situation and the route of zzso zzso treatments of the main zzso side effects of the zzso and actions to be taken in the event of accidental zzso 

zzso zzso is the treatment first recommended for zzso pain insufficiently relieved by WHO level I and II zzso The new zzso zzso forms allow zzso zzso and the treatment of breakthrough zzso zzso zzso soon available in France, is recommended for breakthrough pain in patients already under zzso zzso it gives more rapid relied starting after only 5 minutes and it only acts for a short zzso zzso zzso is indicated for stable cancer zzso It is particularly suitable when oral and zzso zzso routes are not available, or for patients with severe zzso zzso is the first zzso recommended in France for severe cancer pain when zzso resistance exists or uncontrolled side effects are present zzso zzso The new zzso and the new zzso forms widen the range of therapeutic zzso Their use is well codified for cancer pain and must still undergo clinical trials for chronic zzso zzso When correctly zzso zzso selection provides a considerable advance in pain zzso 

